Drug Trial Radar · NCT07408024
Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Sep 10, 2025
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Toll Biotech Co. Ltd. (Beijing)Industry
- Sponsor type
- Industry
- First posted
- Feb 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate the safety, pharmacokinetic (PK) characteristics, and preliminary efficacy of a new oral chemical drug in : adults aged 18-70 years (male or female) with moderate to severe active rheumatoid arthritis (RA), who have had inadequate response to or intolerance of at least one conventional synthetic disease-modifying antirheumatic drug (csDMARDs) .
Conditions
- Rheumatoid Arthritis (RA)
Interventions
TollB-001Drug
TollB-001 Tablets
PlaceboDrug
Placebo Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety-AE/lab tests/PE/VS/ECGTime frame: up to week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.